U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06865677) titled 'Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas' on March 07.
Brief Summary: Background:
Cancers of the female reproductive organs often come back after treatment. A drug called sacituzumab govitecan (SG) has been approved for use in other types of cancers. Researchers want to see if SG can also help people with ovarian, endometrial, or cervical cancers.
Objective:
To test SG in people with ovarian, endometrial, or cervical cancers.
Eligibility:
People aged 18 years and older with ovarian, endometrial, or cervical cancer. Their cancers must have returned after at least 2 rounds of standard trea...